ReviewFrontiers in psychiatry2025
Fear of disease progression and relapse in multiple sclerosis: a systematic scoping review.
Review in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prevalence and associated factors of fear of progression in patients with heart failure in China: a scoping review.Frontiers in psychiatry · 2026Review
- Associations of fear of recurrence and social support with post-traumatic stress disorder and disease recurrence in patients with severe acute pancreatitis: a retrospective study.Frontiers in medicine · 2026Article
- Article
- The role of fear of relapse in quality of life among patients with relapsing-remitting multiple sclerosis.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) is a chronic disease of the central nervous system, most commonly affecting individuals in early adulthood. Uncertainty about future relapses and accumulating disability may lead to significant psychological distress, contributing to reduced quality of life. Objective: This systematic scoping review aimed to synthesize current evidence on the prevalence, determinants, and consequences of fear of relapse and disease progression in people living with MS. Method: The current systematic scoping review followed PRISMA-ScR guidelines. PubMed, Scopus, and Web of Science were searched from inception until October 6 Results: Our search yielded 43 studies, of which 13 met the eligibility criteria. Nine studies utilized the fear of relapse scale and the remaining four used the fear of progression questionnaire. Fear of progression among MS patients ranged from minimal to severe, with concerns centered on losing independence, relying on external help, and potential medication side effects. In relapsing-remitting MS, fear was particularly associated with uncertainty about disease course, potential disability, and worsening fatigue. Increased fear of relapse and progression was strongly associated with higher levels of fatigue, depression, stress, health anxiety, and lower quality of life. Conclusion: Fear of relapse and progression is common and significantly impacts the lives of people with MS. Future research should focus on evaluating and implementing tailored interventions - including psychological support, educational initiatives, and coping-based strategies - to help patients manage these fears.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.